AbbVie agreed to license Nxera Pharma’s EP4 receptor agonist program aimed at inflammatory bowel disease, with $100 million in upfront consideration and up to $1.37 billion tied to development and commercial milestones. The deal covers global rights through AbbVie’s UK subsidiary, which will develop the gut-targeting approach. AbbVie positioned the transaction as an expansion of its IBD pipeline, leveraging Nxera’s drug-delivery strategy that targets drug action in the gastrointestinal tract. Milestone payments are expected to track successful progression through clinical development and eventual commercialization. For Nxera, the licensing arrangement provides a path to fund development while enabling AbbVie to integrate the program into its broader late-stage IBD strategy. For AbbVie, it adds a potential new MOA option at a time when sponsors continue to expand beyond current immunology targets. The event matters for pipeline competition because EP4 signaling and tissue-targeting platforms could offer differentiation in efficacy, tolerability, or both, if clinical translation follows preclinical rationale.